Request Demo
Last update 24 May 2025
Parimifasor
Last update 24 May 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms LYC-30937, LYC-30937 Enteric coated, LYC-30937-EC |
Target |
Action inhibitors, modulators |
Mechanism F1F0-ATPase inhibitors(F1F0-ATPase inhibitors), Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC18H11Cl2F4N5O |
InChIKeyGPLAWHGEODGIAW-UHFFFAOYSA-N |
CAS Registry1796641-10-5 |
Related
5
Clinical Trials associated with ParimifasorNCT02872285
A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
NCT02764229
A Multicenter Open-label Extension Study to Assess the Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis
NCT02762500
A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Assess the Efficacy and Safety of Induction Therapy With LYC-30937-EC in Subjects With Active Ulcerative Colitis
100 Clinical Results associated with Parimifasor
Login to view more data
100 Translational Medicine associated with Parimifasor
Login to view more data
100 Patents (Medical) associated with Parimifasor
Login to view more data
100 Deals associated with Parimifasor
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Chronic large plaque psoriasis | Phase 2 | United States | 05 Dec 2016 | |
| Colitis, Ulcerative | Phase 2 | United States | 01 Nov 2016 | |
| Colitis, Ulcerative | Phase 2 | Czechia | 01 Nov 2016 | |
| Colitis, Ulcerative | Phase 2 | Hungary | 01 Nov 2016 | |
| Colitis, Ulcerative | Phase 2 | Netherlands | 01 Nov 2016 | |
| Colitis, Ulcerative | Phase 2 | Poland | 01 Nov 2016 | |
| Colitis, Ulcerative | Phase 2 | Serbia | 01 Nov 2016 | |
| Ulcerative colitis, active severe | Phase 2 | United States | 01 Jul 2016 | |
| Ulcerative colitis, active severe | Phase 2 | Canada | 01 Jul 2016 | |
| Ulcerative colitis, active severe | Phase 2 | Czechia | 01 Jul 2016 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 33 | Placebo | eprdcftifp(kifovmtaey) = dsjxqjziyo kjcvglzoon (lfofgepkou, 19.67) View more | - | 02 Apr 2019 | ||
Phase 2 | 124 | (LYC-30937-EC 25 mg PO QD) | rigmjogbrn = llkedrnfwc wlgokovvgn (ifklhnzvlk, mvnposuqlf - lkmuzttgyz) View more | - | 02 Apr 2019 | ||
Placebo (Placebo PO QD) | rigmjogbrn = vccvzmdzfj wlgokovvgn (ifklhnzvlk, pdnccvyemi - jqsyfkgxve) View more | ||||||
Phase 2 | 112 | sjfjsgkhsh = evtpfybtgm obxjdhtfjk (wqykrgmrit, huwsqwbhwp - cbghbehqaq) View more | - | 27 Mar 2019 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free